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Background: Chronic airway inflammation characterizes patients with cystic fibrosis (CF). The role of alternative macrophage activation in this
disease course is unknown.
Objective: We evaluated markers of alternative and classical macrophage activation in the lungs of patients with CF and evaluated these
characteristics in the context of Pseudomonas aeruginosa (PA) infection, immunomodulatory drug therapy and pulmonary function.
Methods: Bronchoalveolar lavage or spontaneously expectorated sputum samples were collected from 48 CF patients. Clinical data were related to
macrophage surface expression of mannose receptor (MR) (up-regulated in alternatively activated macrophages) and TLR4 (up-regulated in
classically activated macrophages). Also, the activity of the alternatively activated macrophage effector molecule arginase was compared among
patient groups, and pro- and anti-inflammatory cytokines produced by alternatively and classically activated macrophages were measured.
Results: There were significant differences between PA-infected and -uninfected patients in several clinical measurements. PA-infected patients
exhibited increased use of azithromycin, up-regulation of MR on CD11b+ cells and increased arginase activity in their lung samples, and had a strong
inverse relationship betweenMR and arginase activity to FEV1. Upon further analysis,PA-infected patients whowere treated with azithromycin had the
highest arginase activity and the highest number of macrophages that were MR+TLR4−, and both of these markers were inversely related to the FEV1.
Conclusions: Our findings suggest an increase in both MR and arginase expression as pulmonary function declines in PA-infected patients with
CF. These markers of an alternatively activated macrophage phenotype give cause for future study to define the function of macrophage activation
states in the CF lung.
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The disease process in cystic fibrosis (CF) is in large part a
result of the chronic host inflammatory response. The airways
of these patients are often chronically infected by mucoid
Pseudomonas aeruginosa (PA) which proliferates a cycle of
airway inflammation, airway remodeling, re-infection, and
tissue damage [1–3]. The ongoing response of immune cells
to this chronic infection results in progressive lung destruction,
increased exacerbations of disease, and increased mortality [4].d by Elsevier B.V. All rights reserved.
Table 1
Patient characteristics.
Overall Pseudomonas-
infected
Non-
Pseudomonas
N 48 25 23
Age, years ⁎ 14 (1–50) 16.5 (8–50) 13 (1–25)
Sex, (% male) 56.2% 48% 65.2%
FEV1 (% predicted) ⁎ 65 (13–125) 44.5 (13–83) 89 (39–125)
Source of sample ⁎
BAL 35.4% 44% 26.1%
Sputum 64.6% 56% 73.9%
C reactive protein ⁎ 0.7 (0.5–16.5) 1.7 (0.5–16.5) 0.55 (0.5–1.8)
Peripheral leukocytosis ⁎ 8.6 (4–21.9) 10.6 (4.4–21.9) 7.1 (4–14.6)
Other infection a, ⁎ 68.8% 48% 91.3%
Systemic azithromycin ⁎ 64.6% 84% 43.5%
Systemic steroids 16.7% 20% 13%
Inhaled steroids 54.2% 64% 43.5%
CFTR mutation
Homozygous F508del 47.9% 44% 52.2%
Heterozygous F08del 35.4% 36% 34.8%
Non-F508del 8.3% 12% 4.3%
Unknown 8.3% 8% 8.7%
Note: continuous variables are described with median and range (min–max) or
as % of group.
a Other infection includes one or more of the following: Staphylococcus aureus
(MRSA and MSSA), H. influenzae, S. maltophilia, S. marcescens, A.baumannii,
K. oxytoca, A. xylosoxidans, B. bronchiseptica, and A. fumigatus.
⁎ pb0.05 between groups.
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the innate host response against infection, maintaining homeo-
stasis, and mediating inflammation. Exposure of macrophages to
either the Th1 cytokine interferon (IFN)-γ or the Th2 cytokines,
IL-4 and IL-13, induces two distinct phenotypes deemed
classically (CAM) or alternatively activated macrophages
(AAM), respectively [10,11,22,23]. These cells function as part
of a comprehensive host defense process that includes initiation of
inflammation, clearance of pathogens and extracellular debris,
tissue homeostasis, and repair [5]. The combined action of IL-4
and IL-13 provides an elegant strategy for host protection against
certain infections, but in other cases (e.g. asthma) the effector
functions induced by these cytokines can have pathologic con-
sequences [29]. Recent studies have described the importance of
the AAM effector molecule arginase in patients with asthma,
chronic obstructive lung disease (COPD), CF, pulmonary hyper-
tension, and interstitial pulmonary fibrosis [30]. AAMs and
CAMshave been defined on a continuum of activation states [7,8]
with AAMs typically demonstrating an increased expression of
mannose receptor (MR) [9], low expression of toll-like receptor 4
(TLR4) [11], and up-regulation of arginase [12] relative toCAMs.
The function of AAMs has mostly been defined in the context
of infections with pathogens that trigger Th2-type responses and
in fibrotic diseaseswhere chronic infections have not been present
[13]. Data describing the role of AAMs in response to bacterial
infections is scant. In CF patients who are chronically infected
with PA, the immune response is triggered and maintained, but
this response is ineffective in the clearance of mucoid strains of
PA and promotes alveolar wall thickening, airway remodeling,
and eventual pulmonary decline [6,13,24,31]. The contribution of
AAMs to the process of lung remodeling and fibrosis is just
beginning to be evaluated. AAMs are involved in the fine tuning
of CAMs and Th1 inflammatory responses by driving Th2
polarization, actively inhibiting CAM-driven inflammatory
processes, and mediating repair through up-regulation of the
arginase pathway and other proteins including TGFβ [11,13,14].
Arginase has been postulated to be an important mediator of
airway remodeling and lung fibrosis in patients with CF [19], and
others have described how arginase-controlled production of
collagen precursors increases in CF patients in an age-dependent
manner [25]. Whether AAMs are helpful (through suppression of
dysregulated inflammatory responses) or harmful (through
increased fibrosis development) during a chronic infection such
as occurs with PA in CF patients remains unclear.
We have previously reported that azithromycin (AZM) can
polarize macrophages in vitro toward an AAM-like phenotype
[20]. Because of this and because of the effective clinical use of
AZM as an immunomodulatory agent in CF patients, we are
interested in describing the role of AAMs in the pathophysiology
of CF. The present study describes the activation status of CD11b+
cells in the airways by characterizing surface marker expression
(MR and TLR4), airway cytokine concentrations, and expression
of arginase in PA-infected and -uninfected CF patients. We then
relate these to the patient's pulmonary function as defined by
the forced expiratory volume in 1 s (FEV1). We postulated that
PA-infected patients would have a predominant AAM phenotype
in their bronchoalveolar lavage (BAL) or sputum and that AZM-treated patients would have an increased proportion of markers
associated with AAMs than those not treated with AZM. These
data will lay a foundation for future studies examining the function
of various macrophage phenotypes in the CF lung.
2. Methods
2.1. Population
Forty-eight patients with CF participated in this observational
study. Subjects were match based on PA status only. The
diagnosis of CF had been confirmed by genetic analysis (Ambry
Genetics, CA) demonstrating two disease causing mutations and/
or 2 separate sweat chloride tests (N60 mEq/l) and clinical
features consistent with the disease in all subjects. BAL fluid was
collected from 17 acutely ill patients undergoing bronchoscopy as
part of their medical care at the University of Kentucky Medical
Center (UKMC). Sputa were collected from 31 clinically stable
CF patients (i.e., no acute exacerbation, upper respiratory infec-
tion, or requirement for an antibiotic (other than AZM main-
tenance) during the 4 weeks prior to collection) who were able to
spontaneously expectorate sputa during routine clinic visits at
UKMC. Table 1 lists the characteristics of the enrolled patient
population. Overall, 27male and 21 female patients were enrolled
between the ages of 1 and 50 years. The cohort was under the age
of 25 years with the exception of two participants who were 49
and 50 years old.
Spirometry was performed using Knudson criteria [15] on the
same visit as the sputum sample collection or within a week before
the BAL sample. Serum C-reactive protein and leukocyte count
were measured on the same day as the sample was collected.
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steroids if they had received the treatment for at least one month
prior to the sample collection.AZMdoses ranged between 250 mg
and 500 mg daily or every other day. Subjects and/or legal
guardians provided written informed consent/assent as approved
by the Internal Review Board at UKMC.
2.2. Sample processing
Two to 5 ml of sputum or BAL fluid was collected and
immediately placed on ice. For BAL samples, up to 60 ml of room
temperature saline was used for the lavage. A 3–5 ml aliquot of
the first lavage was obtained for analyses for the purposes of this
study. Sputum samples were processed by digestion in 0.1%
diothiothreitol and DNase 30 μg/ml for 30 min [28]. The sputum
sample was deemed adequate for further analysis if there were
b10 epithelial cells and N25 white blood cells per lower powered
field (10×). Digest supernatants were frozen at−80 °C. Cells were
washed thrice to create single cell suspensions and immediately
processed. Since each lavage may have had a different diluting
effect on the concentration of BAL fluid contents, cytokine
concentrations were normalized to total protein concentration to
correct for this as has been previously described [16]. Total protein
concentrationswere assessed using theMicroBCA (bicinchoninic
acid) protein assay reagent kit (Pierce Biotechnology).
Microbiological analysis of patients' sputa and BAL fluid
included the following: 1) a semi-quantitative evaluation on non-
selective medium, 2) isolation of respiratory pathogens, and 3)
antimicrobial susceptibility testing by single-disk diffusion test
(Kirby–Bauer). These studies were performed by the UKMC
ClinicalMicrobiologyLaboratory usingmethods approved by the
Clinical and Laboratory Standards Institute.
2.3. Flow cytometry
Cells isolated fromBAL fluid and sputumwere incubatedwith
fluorescently-labeled monoclonal antibodies specific for CD11b,
MR, and TLR4. The monocyte marker CD11b is up-regulated on
infiltrating monocytes/macrophages and was used to identify this
group of cells, and MR and TLR4 were chosen based on their
differential levels of expression in AAMs and CAMs, respec-
tively [8–10]. Cells were analyzed by multiparameter flow
cytometry using a FACSCalibur Flow Cytometer (BD Bios-
ciences,MountainView, CA). Greater than 50,000 events/sample
were examined. Cells were classified by gating on characteristic
size and granularity, thereby eliminating lymphocytes, apoptotic
cells, and debris. The remaining fraction positive for CD11b
surface expression were then individually assessed for expression
of MR and TLR4.
2.4. Arginase activity
Arginase activity was assessed via the measurement of the
conversion of L-arginine to urea [17]. Briefly, 10 mM MnCl2 in
Tris–HCl was incubated with cell lysates and L-arginine
overnight. The reaction was terminated by the addition an
acid solution. Alpha-isonitrosopropiophenone 9% in ethanolwas added to each tube and the OD was read using a 490 nm
filter. Readings were compared to a standard curve of known
urea concentration. A unit of arginase activity converts 1 μmol
of L-arginine to urea per minute.
2.5. Cytokine assays
IL-10, IL-12, TNFα, IL-6, IL-1β, and IL-8 from CD11b+
cells were simultaneously measured in the cell lysates using
Cytometric Bead Array kits (BD Pharmingen, San Jose, CA)
with a limit of detection of 3.3 pg/ml, 4 pg/ml, 3.7 pg/ml,
2.5 pg/ml, 7.2 pg/ml, and 3.6 pg/ml, respectively [18,21]. Bead
populations with distinct fluorescence intensities coated with
capture antibodies specific for each cytokine were incubated
with detection antibodies along with each sample. Fluorescence
intensities were assayed by flow cytometry and compared with
a standard curve to determine the concentration.
2.6. Statistical analyses
The primary objective was to ascertain whether AAM surface
markers and arginase activity correlated with a particular patient
profile based upon FEV1 and PA infection status. The secondary
objective was to determine if AZMwas an important determinant
of the predominant macrophage phenotype. Patients were
grouped based on PA-infection status. Categorical data were
analyzed using the chi-square test of independence or Fisher's
exact test where appropriate. Data that failed normality testing
were compared using the Mann Whitney Rank Sum Test,
otherwise a two-sample t-test was performed. Surface receptor
expression and arginase activity were correlated to FEV1 using
the Pearson Product Moment Correlation with subsequent
forward and backward stepwise multiple regression. Since the
data presented in this study was of a hypothesis-generating and
exploratory in nature, multiple test adjustments were not per-
formed. Differences were determined to be statistically significant
when a p-value of b0.05 was attained. All analyses were per-
formed using SigmaStat 3.5 (Systat Software, Chicago, IL).
3. Results
3.1. Patient groups
Patient characteristics and differences between the PA-
infection groups are shown in Table 1. There was no significant
difference in the number or males and females between the PA-
infection groups (p=0.3). Gender made no difference when
comparing arginase activity, surface receptor expression, and
cytokine concentrations between the 2 groups (pN0.1). The
median age of the PA-infected group was significantly higher
(pb0.05), and patients who were above the median age of 14
were more likely to be infected with PA (pb0.001). However,
there were no differences in arginase activity, surface receptor
expression or cytokine concentrations between males and
females. The groups also did not differ in terms of CFTR
gene mutations present (pN0.5).
Fig. 1. Box and whisker plots of macrophage markers in Pseudomonas-infected
and -uninfected patients as measured by (A) percentage of CD11b+ cells with
up-regulation of MR expression, and (B) arginase activity. MR expression on
CD11b+ cells was determined by flow cytometry. Arginase activity was
measured by the fluorimetric measurement of the conversion of L-arginine to
urea. pb0.0001 for differences between median MR expression and arginase
activity. Box plots demonstrate medians, range, 5th and 95th percentiles with
outliers demonstrated for each.
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median FEV1 values of the PA-infected and -uninfected groups
differing significantly (44.5% vs. 89%, respectively; pb0.05).
The median FEV1% between males and females (regardless of
age, PA status or AZM status) was not significantly different
(p=0.57). As expected, the FEV1 was lower among patients
who were older than the median compared to those who were
younger (80.2% vs. 52%, respectively; p=0.001).
There was no significant difference in the PA-infection status
between patient groups whose samples were obtained by
spontaneous expectoration vs. BAL sample (p=0.32). Serum
markers varied significantly between the groups with PA-
infected patients having a higher median peripheral leukocyte
count and C reactive protein value (pb0.05).
Finally, patients in the two groups received different therapies.
Patients infected with PA were more likely to have received
AZMN4 weeks (pb0.05). Importantly, there was no difference
between AZM use between males and females, no difference in
AZM use between patients above and below the median age, and
the rates of inhaled and oral steroid use were not significantly
different between groups (pN0.3).
3.2. Surface markers, arginase activity and cytokines
We then asked whether the prevalent macrophage activation
state as measured by surface receptors, cytokine production and
arginase activity was different between the groups. While
leukocyte differential counts were not performed, the mean
percentages±standard error of CD11b+ cells (infiltrating mono-
cytes) were 35.0%±4.3% and 39.5%±4.5% for the PA-infected
and -uninfected groups, respectively (p=0.49). Differences in the
mean percentages of CD11b+ cells between BAL and sputum
samples were not observed (p=0.98). The median percentage of
CD11b+ cells expressing high levels of MR was significantly
higher in the PA-infected group than in the PA-uninfected group
(32.46% vs. 13.03%, p=0.014) (Fig. 1A). However, there was no
significant difference in the median mean fluorescence intensity
(MFI) ofMR (pN0.1). TLR4 expression on CD11b+ cells did not
differ between the groups (pN0.5). Samples from PA-infected
patients had higher arginase activity than samples from PA-
uninfected patients (1.99×10−4 U/mg protein vs. 8.01×10−5 U/
mg protein; pb0.001) (Fig. 1B).
Finally, cytokines were measured in BAL and sputum and
normalized to 500 μg of total protein. There were no significant
differences between the concentration of TNFα, IL-6, and IL-10
between the groups (pN0.1). However, PA-infected patients
had higher concentrations of IL-12 (16.2 pg/ml vs. 11.5 pg/ml,
p=0.02), IL-1 (398.02 pg/ml vs. 198.7 pg/ml, p=0.03), and a
trend toward higher IL-8 concentrations (5304.2 pg/ml vs.
2910.35 pg/ml, p=0.07) (Fig. 2).
3.3. Relationship of activation markers to FEV1
The relationship with markers of alternative macrophage
activation and disease severity were analyzed utilizing FEV1 as a
clinical measurement of a patient's pulmonary status. Correlation
coefficients (r) and p-values for each relationship tested are givenin Table 2. Patients infected with PA were more likely to have an
FEV1 less than the median (OR=15, CI 3.6–61.9). Overall, there
was a significant inverse relationship between the percentage of
CD11b+ cells expressing MR and FEV1 (r=−0.55, p=0.001)
(Fig. 3A) and between FEV1 and the degree to which MR was
expressed as defined by the MFI (r=−0.304, p=0.05). Further
subset analysis revealed a negative trend in the relationship
between MR expression and FEV1 in PA-infected patients (r=
−0.407, p=0.06) and a strong inverse relationship between FEV1
and MR in the PA-uninfected patients (r=−0.662, p=0.001).
This result corresponds with the median MR data above, as
infected subjects were primarily those within the lower FEV1
range. There was no significant relationship between expression
of TLR4 on CD11b+ cells and FEV1 (pN0.1).
Similarly, we sought to characterize the relationship between
arginase expression and disease severity. We observed a strong
inverse relationship between arginase activity and FEV1 when
analyzing values from all patients (r=−0.483, p=0.002) (Fig. 3B).
This association was strongest in the PA-infected patients (r=
−0.567, p=0.02), and further analysis of this patient subset
showed that the relationship between arginase activity and FEV1
was greatest among those whose FEV1 was b65% predicted
(p=0.003).
Fig. 2. Comparison of median cytokine expression in cell lysates from patients with CF who were Pseudomonas-infected and -uninfected. Cytokine concentration
was determined by a multiplex assay. Box plots demonstrate medians, range, and 5th and 95th percentiles with outliers demonstrated for each cytokine.
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to FEV1 (r=−0.486; p=0.016). There was a trend in IL-10's
inverse relationship to FEV1 (r=−0.36, p=0.08) and between the
concentration of IL-12 and FEV1 (r=−0.524, p=0.06). However,
in subset analyses of the PA-infected group, IL-12 concentration
displayed a strong direct relationship to FEV1 (r=0.474, p=0.01).
The ratio of the anti-inflammatory cytokine IL-10 to the pro-
inflammatory IL-12 was significantly inversely related to FEV1
(r=−0.739, p=0.038). None of the other cytokine concentrations
measured correlated to FEV1 (pN0.2).Table 2
Relationship of FEV1 to markers.
MR expression MR+TLR4− expression
Grouped by: r p r p
Overall −0.550 0.001 NS
PA-infected −0.407 0.06 NS
PA-uninfected 0.662 0.001 NS
AZM treated NS −0.482 0.048
AZM untreated −0.391 0.08 NS
PA+AZM+ NS −0.615 0.039
PA+AZM− NS NS
PA−AZM+ NS NS
PA−AZM− NS NS
NS = non-significant p-valueN0.1.3.4. Comparison of sample source
Because of the difference between the source of the samples
(BAL vs. sputa) in the groups (p=0.065), subset analysis of the
surface receptors and arginase activity was performed. The
percentages of isolated cells that were CD11b positive were
compared between sample sources. Mean percentages from
BAL and sputum samples that were CD11b positive were not
significantly different (37.5±24.3% and 37.8±15.8%, respec-
tively, p-value=0.975). There was no difference in relationshipsArginase activity TNFα IL-10
r p r p r p
−0.483 0.002 −0.486 0.016 −0.36 0.08
−0.567 0.02 NS NS
NS NS NS
−0.380 0.025 −0.728 0.004 NS
NS NS NS
−0.69 b0.001 NS NS
NS NS NS
NS NS NS
NS NS NS
Fig. 3. Relation of FEV1 and (A) surface expression of MR on CD11b+ cells and
(B) arginase activity in sample lysates from PA-infected and -uninfected
patients. Lines represent the linear regression analysis between the variables for
the infected (– – –) and uninfected (—) groups.
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concentrations or arginase activity when the data was analyzed
only in terms of the source (pN0.4 for all parameters).
3.5. Comparison of AZM and steroid treatment
Since our previous work demonstrated that AZM can induce
properties of alternative macrophage activation, we were
interested in evaluating macrophage activation markers relative
to AZM exposure. There was no significant difference between
AZM-treated and -untreated patients in regards to the median
arginase activity (1.19×10−4 vs. 8.95×10−5 U/mg protein, respec-
tively; pN0.5), surface receptor expression (pN0.2), or cytokine
concentration (pN0.5).
Table 2 shows there were no significant relationships between
FEV1 and the percentage of CD11b+ cells that had up-regulated
MR expression among either AZM-treated or -untreated subjects
(pN0.05); however, the percentage of CD11b+MR+TLR4− cells
in the AZM-treated group directly related to the FEV1 (r=
−0.482, p=0.048). Arginase was inversely related to FEV1 in the
AZM-treated group (r=−0.38, p=0.025) but not in the AZM-
untreated group (p=0.24). Additionally, there was a trend toward
significance in the relationship between TLR4 surface expressionand FEV1 in the AZM-treated patients (r=0.342, p=0.06) that
was not observed in the untreated group (p=0.16).
Among AZM-treated patients, FEV1 and TNFα concentra-
tion were inversely related (r=−0.728, p=0.004). No other
relationships were found between FEV1 and any of the other
cytokines.
Further subgroup analyses were performed taking into
consideration both PA infection and AZM treatment status.
The median arginase activity in the sample differed between
AZM+PA+ (n=20) and AZM−PA− (n=12) groups (p=0.006)
and between AZM+PA− (n=8) and AZM−PA− (n=8) groups
(p=0.015). The relationship between arginase activity and
FEV1 was found to be greatest among AZM+PA+ subjects (r=
−0.69, pb0.001) (Fig. 4A). Likewise, AZM+PA+ patients had
the highest percentage of CD11b+ MR+TLR4− cells (6.5%,
p=0.009). Among these patients, this same cell population
inversely correlated to FEV1 (r=−0.615, p=0.039) (Fig. 4B).
No significant correlationswere found between FEV1 and arginase
activity, surface receptor expression, or cytokine expression in any
of the other subgroups (pN0.1).
Because of the overlap in AZM and oral steroid use in the
groups, we repeated the analysis and excluded AZM-treated
patients who also were receiving oral steroids. For the 13
patients treated with AZM and not steroids, there was no
significant change of the relationships that are reported above
for MR expression and arginase activity (pb0.02). In the 12
patients who were treated with either inhaled or oral steroids but
not AZM, no significant correlations were found between FEV1
and any of the markers measured in this study (pN0.1).
3.6. Infection with a non-PA organism
Overall 68.8% of the total patients were infected with at least
one other organism other than PA (including Staphylococcus
aureus, Haemophilus influenzae, Stenotrophomonas maltophi-
lia, Serratia marcescens, Acinetobacter baumannii, Klebsiella
oxytoca, Achromobacter xylosoxidans, Bordetella bronchisep-
tica, and Aspergillus fumigatus). PA-uninfected patients
demonstrated a higher prevalence of infection with at least
one additional organism in the lungs as compared to the PA-
infected group (91.3% vs. 48%, respectively; pb0.05). The
predominant non-PA organism was S. aureus (methicillin
resistant (MRSA) and sensitive (MSSA)). Twenty percent of
PA-infected patients and 26% of the PA-uninfected patients
were infected with MRSA; 20% of the PA-infected patients and
52% of the PA-uninfected patients were infected with MSSA.
To evaluate possible interactions between PA and/or any of
these other organisms that could affect macrophage activation
states, subset analyses were performed of patients who were
infected with only PA, those who were infected with PA and
another organism, and those who were only infected with a non-
PA organism. Infection with organisms other than PA did not
significantly affect whether patients had FEV1 measurements
above or below the FEV1 median (OR=0.73, CI=0.03–18.19).
Analyses revealed no significant interactions between any non-
PA organism and FEV1 or any of the inflammatory markers
evaluated in this project, although power to detect differences
Fig. 4. Relation of FEV1 to (A) arginase activity and (B) percentage of CD11b+
cells that were both MR+ and TLR4− among patients who are AZM-treated and
PA-infected. Lines represent the linear regression analysis between the
variables.
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group analyses did not significantly change any of the reported
differences or correlations that exist between the PA-infected
and PA-uninfected groups.3.7. Prediction of FEV1
To determine whether characteristics of AAMs were
predictive of a patient's overall disease severity, we performed
a multiparameter modeling analysis of the impact of all
measured variables upon FEV1. Of the factors evaluated, the
FEV1 in CF patients enrolled in this study can best be predicted
from a linear combination of the patient's age (pb0.001), PAinfection status (pb0.001), AZM treatment status (p=0.003),
macrophage MR surface expression (p=0.013), and arginase
activity (p=0.032). Therefore, it can be concluded that even
controlling for other factors, MR and arginase activity are still
significant.
4. Discussion
This study shows that the BAL fluid and sputum from PA-
infected patients with CF contain a population of CD11b+ cells
that have an increase in characteristics consistent with an AAM
phenotype (i.e., higher percentage of MR expression and high
arginase activity). Further, AZM treatment of PA-infected
patients was associated with the highest percentage of CD11b+
MR+TLR4− cells and highest arginase activity. This is the first
study correlating select characteristics of alternative macro-
phage activation to pulmonary function and is the first study
evaluating the association between these AAM markers and the
use of AZM in patients with CF. These data support the
hypothesis that AAMs are relevant in the pathophysiology of
chronic PA infection in CF patients and relate to our previous
description of AZM's ability to polarize the macrophage toward
the AAM phenotype [3].
While the role of alveolar macrophages in response to lung
pathogens in CF is not completely understood, previous studies
have implicated a potential role of the AAM-activation cytokines
IL-4 and IL-13 in the disease process. Hartl et al. reported that
BAL fluid frompatients withCF infectedwithPA had higher IL-4
and IL-13 concentrations and lower levels of IFNγ compared
with uninfected patients, and BAL fluid levels of IL-4 and IL-13
correlated inversely with FEV1 [5]. Additional studies have
shown that, in response to PA outer membrane proteins, mono-
cytes from PA-infected CF patients produce more IL-4 and less
IFNγ than monocytes from non-PA-infected patients [6]. These
studies support the notion that alternative macrophage activation
may be prevalent in CF patients with declining pulmonary func-
tion. Our work extends these investigations further by examining
the impact that this shift has upon the activation state of the
macrophage compartment in CF patients. There are also further
implications of a relationship between a CD11b+ MR+TLR4−
cell and high activity of arginase-1, recognized as one of the most
specific AAM markers and an important mediator of airway
remodeling and lung fibrosis [19]. However, it remains to be
determined whether the increased prevalence of AAMs in PA-
infected patients is a beneficial alteration of an immune system
that is compensating for a progressive pathology or if this indeed
contributes to airway damage and fibrosis.
Several possibilities exist to explain the expression of MR
and increased arginase activity in patients infected with PA. The
IL-4/IFNγ imbalance that exists in CF patients [5] suggests that
the cytokine environment in chronic PA-infected lungs drives
the macrophage phenotype. Because the main purpose of this
project was to characterize the macrophage activation status we
did not measure IL-4 and IL-13 concentrations. However, it is
possible that increased IL-4/IL-13 in the patients with
decreasing FEV1 could have driven the macrophage response
toward a prevalence of alternatively activated macrophages.
321B.S. Murphy et al. / Journal of Cystic Fibrosis 9 (2010) 314–322Still, there were no significant differences between anti- and
pro-inflammatory cytokines between the AZM and PA
subgroups that could alone explain these differences.
Due to the observational nature of this study, there are several
limitations. As patients decline clinically, they are more likely to
be infectedwithPA, and physicians aremore likely to start empiric
therapies with AZM. Hence, we were unable to infer causality
between the macrophage phenotype that predominates in the lung
of the CF patient at any point in time to the patient's lung function
or to medications such as AZM with which a patient is treated.
Additionally, because some samples were collected from sputum
and somewere collected duringBAL,we are unable to completely
compare differences that could occur between alveolar macro-
phages and macrophages in the central airways, respectively.
Differences in neutrophil andmacrophage counts between sputum
and BAL fluid have been described previously [37]; it is possible
that by increasing the numbers of patients enrolled in the study or
by comparing patients matched for age and disease severity we
would detect differences in macrophage phenotypes between the
sample sources. It is important to note that we primarily matched
patients based on PA-infection status. Our study confirms the
results of other studies that have shown high concordance between
expectorated sputum and BAL samples in regard to microbial
burden [38]. Nonetheless, the subset analyses of AZM exposure
and PA infection status suggest that the strongest correlation
between AAM markers and decline in pulmonary function are
found among patientswho are treatedwithAZMand infectedwith
PA, regardless of the source of the sample.
It is difficult in this study to separate the effects of PA and
AZM since there is substantial overlap of these patient groups.
However, we believe that AZM directly affects macrophage
activation states in PA-infected patients for several reasons: 1)
quantitative microbiological data revealed no significant differ-
ence in PA bacterial burden between groups based on AZM
treatment status, indicating that the AAM phenotype is not
exclusively an effect of clearance of PA; 2) there were overall
correlations between MR and arginase activity to FEV1 that were
found to be strongest among PA-infected patients treated with
AZM; and 3) subgroup analyses of patients co-infected with non-
PA organisms revealed no changes in the differences among
inflammatory markers or correlations to lung function.
An alternative explanation of the data could be due to AZM's
ability to alter bacterial virulence factor production including
biofilm proteins [27]. While this is possibly a contributing
factor, we believe that AZM directly affects the macrophage
based on our previous findings. In our in vitro studies with J774
macrophages, we demonstrate that AZM will polarize cells to
an AAM-like phenotype not only when stimulated with PA
(unpublished) but also when stimulated with purified LPS [20].
The compelling aspect of this work is that AZM polarizes
macrophages to AAM despite exposure to the classical
activation stimuli IFNγ and LPS. We believe this is relevant
in this current study where patients have continual exposure to
PA and its LPS.
Our data support the notion that the preference for AAMs in
the lungs of PA-infected CF patients is dependent on additional
factors other than the exaggerated cytokine response as pro-inflammatory and not anti-inflammatory cytokines predomi-
nated in the lungs of the PA-infected patients. However, it is
possible that the macrophage receptor expression and arginase
activity that we observed in these patients is a result of changes in
cell signaling pathways. While the effect of CFTR expression on
alveolar macrophage's activity is still debated [32,33], it has been
reported that CFTR is a negative regulator of NF-κB mediated
innate immune response [34]. A possible link between the NF-κB
signaling pathway and the control of macrophage activation
characteristics has been reported previously [26], but the
molecular pathways for induction of different macrophage gene
expression programs during PA infection or AZM treatment has
not yet been described in any model, regardless of CFTR ex-
pression. It should be noted that there were no significant dif-
ferences among CFTR mutations between the PA or AZM-
treatment groups in this current study, leading us to conclude that
CFTR expression is not a significant factor in PA or AZM's
polarization of the macrophage phenotype. Still, other variations
in cell signaling and cell programming could cause alveolar
macrophages to differentially express effector molecules, surface
receptors, and cytokines associated with AAMs and CAMs.
Responses governed by NF-κB represent a plausible explanation
for the hyper-responsive and constitutive inflammation seen in the
lungs of patients with CF. Since AZM has been shown to blunt
this hyper-responsiveness by inhibiting NF-κB signaling [35,36],
this may, in part, account for the differences we have observed in
the macrophage activation states.
Our results indicate that characteristics of alternative macro-
phage activation predominate inPA-infected patients with CF and
that this cell population may be relevant to the remodeling and
fibrotic changes that occur during this disease. There are likely
complex interactions between several immune cell populations
that govern inflammation and defense against bacterial pathogens
that predominate in the lungs of patients with CF. Differences in
macrophage activation likely play an important role during the
disease process, and it remains to be determined whether
induction of alternative macrophage activation with drugs such
asAZM is beneficial. The potential long-term effect of an increase
in AAMs, their effector molecules such as arginase, and their
subsequent influence on airway remodeling has only been
demonstrated in other lung diseases where chronic infections
have not been present [13]. Future studies evaluating long-term
use of AZM in PA-infected patients should include evaluation of
the contribution that macrophage phenotype alteration has upon
disease severity and progression.References
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